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Abstract
Following acute myocardial infarction (MI), cardiomyocyte survival depends on its mitochondrial oxidative capacity. Cell
death is normally followed by activation of the immune system. Peroxisome proliferator activated receptor c-coactivator 1a
(PGC-1a) is a transcriptional coactivator and a master regulator of cardiac oxidative metabolism. PGC-1a is induced by
hypoxia and facilitates the recovery of the contractile capacity of the cardiac muscle following an artery ligation procedure.
We hypothesized that PGC-1a activity could serve as a good molecular marker of cardiac recovery after a coronary event.
The objective of the present study was to monitor the levels of PGC-1a following an ST-segment elevation acute myocardial
infarction (STEMI) episode in blood samples of the affected patients. Analysis of blood mononuclear cells from human
patients following an STEMI showed that PGC-1a expression was increased and the level of induction correlated with the
infarct size. Infarct size was determined by LGE-CMR (late gadolinium enhancement on cardiac magnetic resonance), used
to estimate the percentage of necrotic area. Cardiac markers, maximum creatine kinase (CK-MB) and Troponin I (TnI) levels,
left ventricular ejection function (LVEF) and regional wall motion abnormalities (RWMA) as determined by echocardiography
were also used to monitor cardiac injury. We also found that PGC-1a is present and active in mouse lymphocytes where its
expression is induced upon activation and can be detected in the nuclear fraction of blood samples. These results support
the notion that induction of PGC-1a expression can be part of the recovery response to an STEMI and could serve as a
prognosis factor of cardiac recovery.
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Introduction
Acute myocardial infarction (MI) is the leading cause of death of
patients with cardiovascular disease [1,2]. Left ventricular (LV)
dilatation and pump failure following MI are the main causes for
poor clinical outcomes. Clinical studies have consistently demon-
strated that development of congestive heart failure typically
depends on infarct and LV ischemic size areas. MI ischemic
process initiates a cascade of progressive structural and geometric
changes in the left ventricle, a process commonly referred to as
remodeling. The molecular and cellular changes associated with
ventricular remodeling affect both the necrotic zone and the non-
infarcted segments of the ventricle and manifest clinically as
chamber dilation, ventricular remodeling with increased sphericity
of the ventricle and worsened cardiac function, greatly limiting
patients living conditions [3,4].
MI recovery thus depends on two clearly distinct but related
factors. The first one is the capacity of cardiomyocytes to survive
the ischemia-reperfusion (IR) injury, and the second one is the
intrinsic regenerative capacity of the damaged tissue, that depend
both on the patient genetics but also on its life-style and clinical
history. Importantly, not only cardiomyocytes but several other
cell types have been proposed to play a role in the repair/
regeneration process and impact, both positively and negatively,
the final outcome [5]. For example, early activation of the
inflammatory system protects from ventricular remodeling al-
though its sustained activation favors it. Evidence suggests that T
cells play a significant role in controlling the post-infarct
inflammatory response [6]. Their behavior is likely to depend to
a large extent on the capacity of the damaged tissue of recovering
its oxidative capacity. Low oxygen tension activates critical
transcription factors like HIF (Hypoxia Induced Factor) that facilitates
cell survival by shifting the cellular metabolism from oxidative to
glycolytic [7]. If this metabolic shift were not reversed during the
‘‘recovery-regenerative’’ phase the result would be increased
cardiac overload and failure [8]. The crucial regulatory factors/
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pathways that mediate this metabolic shift are still only partially
elucidated [9].
Peroxisome proliferator activated receptor c coactivator -1a
(PGC-1a) is a transcriptional coactivator and a master regulator of
genes involved in oxidative metabolism and mitochondrial
biogenesis [10] that plays a key role in the metabolic control in
the cardiac muscle [11] and participates in cardiomyocyte
differentiation [12]. Importantly PGC-1a knock out mice develop
ventricular dysfunction and are prone to cardiac failure following
transverse aortic constriction [13]. Accordingly, PGC-1a levels are
reduced in the heart following MI by coronary artery ligation in
rats [14] while treatment with angiotensin II receptor blockers
(ARB) and PPAR agonists (pioglitazone and rosiglitazone),
preserve both ventricular function and PGC-1a levels, and have
been demonstrated to attenuate myocardial ischemia-reperfusion
injury [15,16,17]. Another study using rats demonstrated that the
gene expression of PGC-1a was also down-regulated in the heart
in congestive heart failure [18].
All these results support the notion that while severe hypoxia
activates HIF [19] and down-regulates PGC-1a levels in the
cardiomyocyte, PGC-1a induction is likely to be crucial during the
regenerative phase to facilitate the recovery of the cardiac muscle
oxidative capacity [20]. Therefore, monitorization of the patient’s
capacity to induce PGC-1a expression post-infarction would be of
potential use to pre-evaluate its later recovery, however that
monitorization could only be feasible if PGC-1a induction post-
infarction could be detected in the nuclear fraction of blood
samples. In this respect PGC-1a has been previously reported to
be present in circulating neutrophils and lymphocytes [21].
In summary, from what we know so far from PGC-1a biology
we think that the capacity of a tissue to induce PGC-1a after an
hypoxic event, such as a MI, could predict the regenerative
capacity of the tissue. In the particular case of the human heart
following a MI, that predictive value is both particularly relevant
and hard to assess directly, because we cannot take biopsies of the
infarcted heart in order to measure PGC-1a levels. Hence, the
potential use of PGC-1a as a predictor of a patient’s recovery
capacity would have no translational use unless we showed first
that we could detect PGC-1a induction in circulating immune
cells of infarcted patients.
Therefore, we decided to test if PGC-1a could be detected in
human blood mononuclear cells and if its expression was induced
following lymphocyte activation post-infarction.
Our results show that PGC-1a is present and active in both B
and T lymphocytes, and its expression is activated upon
lymphocyte activation. More importantly, PGC-1a induction
can be detected in blood mononuclear cells from MI patients,
72 hours (h) post-infarction, with PGC-1a induction correlating
well with the size of the hypoxic area.
Materials and Methods
Humans
This is a cohort study of 38 patients with confirmed ST-segment
elevation myocardial infarction (STEMI) that were subjected to a
reperfusion strategy and discharged alive from Coronary Care
Unit of the ‘‘Consorcio Hospital General Universitario de
Valencia’’ (CHGUV), Spain. The patients were admitted in the
period from March-2009 through March-2010. The diagnosis of
STEMI was based on the definition of the European Society of
Cardiology (ESC) Guidelines [22,23], by the presence of clinically
appropriate symptoms (ischemic characteristic chest pain and/or
autonomic nervous system activation), increased blood levels of
biomarkers troponin I (TnI) and creatin-kinase MB (CK-MB) and
persistent ST-segment elevation on the electrocardiogram (ECG).
Reperfusion therapy included mechanical and pharmacological
procedures, such as fibrinolytic treatment, primary percutaneous
coronary intervention (PCI) and rescue PCI after failed pharma-
cological reperfusion. For exclusion criteria see Supp. Info. Blood
samples were drawn on admission to the hospital and 72 h later.
Total mRNA and protein were isolated from the blood
mononuclear fraction.
Infarct size was estimated from the determination of the
necrotic area by late gadolinium enhancement (LGE) in cardiac
magnetic resonance (CMR) studies. Maximun CK-MB and TnI
plasma levels, left ventricular ejection function (LVEF) and
regional wall motion abnormalities (RWMA) were also used as
markers of cardiac injury.
Patient exclusion criteria
Were excluded patients with previous history of coronary artery
disease, in order to avoid bias measuring myocardial necrosis
images obtained by CMR. We also excluded patients with chest
pain latency longer that 150 minutes, to avoid miss interpretation
of the results obtained from blood samples at the time of hospital
admission. Moreover, patients resuscitated, those that suffered a
second infarction in the first 72 h post admission, or having their
highest CK value on admission, were also not included in the
study. The presence of left bundle branch block or atrial
fibrillation of ECG at admission was also an exclusion criteria.
Clinical data collected included: clinical history including, cardio-
vascular risk factors and ambulatory treatment, relevant biochem-
ical values, including fasting glucose (mean of three independent
values), hemoglobin and hematocrit at admission, leucocytes at
admission and 72 h later (including total leucocytes, lymphocytes,
monocytes and their relative percentages), CRP at admission,
creatinine at admission and the glomerular filtration rate estimated
by MDRD equation, lipid profile (including total cholesterol,
LDLc, HDLc and triglycerides), glycosilated hemoglobin (Hb1Ac),
and the plasma curve of cardiac biomarkers (peak values were used
for the analysis), reperfusion procedure used (pharmacological
strategy with tenecteplase or mechanical process as primary or
recue PCI), echocardiographic data, performed on the first 72 h,
with all the M-mode parameters and two dimensional analysis,
including LVEF and RWMA, hemodynamic data, including
LVEF by ventriculography and coronary arteries affected by the
coronarography (considering significant stenosis those with more
than 75% of the vessel lumen of epicardial coronary arteries or
more than 50% of the main left artery, and CMR data, including
the regular determinations of both ventricles, their EF and
myocardial mass, the necrotic mass estimated by late gadolinium
enhancement (LGE), and the presence of microvascular obstruc-
tion).
Cardiac Magnetic Resonance (CMR) studies
CMR was performed with a 1.5 T unit (Magneton Sonata,
Siemens, Erlangen, Germany). Functional images of long-axis and
short axis were obtained using ECG-gated SSFP (Steady State Free
Precession) sequences (8 mm slice thickness with 2-mm gap between
short-axis slices). Edema detection was carried out using short-axis
black-blood, T2-weighted (short time inversion recovery) in the
same views as the cine sequences using a HASTE (Half-Fourier
Acquisition Single-shot Turbo spin Echo) multisection sequence (RT, 2
R-R intervals; ET, 33 ms; IT, 170 ms; slice thickness, 8 mm;
inter-slice interval, 2 mm; flip angle, 160u; matrix, 2566151;
bandwidth, 781 Hz/pixel) and a segmented TSE (Turbo Spin-Echo)
sequence (RT, 2 R-R intervals; ET, 100 ms; IT, 170 ms; slice
thickness, 8 mm; interval, 2 mm; flip angle, 180u; matrix,
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2566146; bandwidth, 235 Hz/pixel) in case of poor quality with
HASTE sequence. Late-gadolinium images were acquired after
intravenous injection (0,15 ml/kg) of dimeglubine gadobenate
0.5 M. Non breath-holding ECG-gated single-shot IR-SSFP
short-axis in the same views as the cine sequences were performed
1–2 min after contrast administration with fixed long TI (600 ms)
to discriminate normal myocardium, infarcted myocardium and
microvascular obstruction (MVO). Ten minutes after contrast
administration, the same short-axis slices were repeated adjusting
the IT to null normal myocardium using non breath-holding
single-shot IR-SFP sequences and finally breath-holding 2D and
3D turbo-FLASH (Fast Low Angle Shot) sequences. A standard 17-
segmented cardiac-model was used for short-used for short-axis
slice segmentation and assessing areas of edema and late-
gadolinium images. Perfusion defects were assessed visually as
persistent deficit during the first–pass contrast. Areas of high T2
signal intensity were identified by visual inspection. Finding of a
low-signal-intensity area surrounded by a high-signal-intensity
area in these images was considered to indicate an area of MVO.
Areas with LGE were also identified by visual inspection, where
MVO was defined as an area without signal located within an area
of LGE. Transmurality was considered when the area of affected
myocardium was.50%. Both edema and LGE were evaluated by
manual tracing of these areas, and given values are expressed as
percentage of total myocardium mass, as calculated by tracing
endocardium and epicardium contours in a dedicated work-station
(Argus, Siemens, Erlangen, Germany).
Mice
C57BL6 PGC-1a2/2 mice were originally provided by Dr.
Bruce Spiegelman (DFCI, USA) and following embryonic transfer
a colony was established within the SPF area of the CNIC animal
facility. Male C57BL6 PGC-1a+/+ and PGC-1a2/2 of 6–8 weeks
of age were used.
Preparation of splenocytes and thymocytes from mice
Spleen and thymus were removed aseptically. Single-cell
suspensions were obtained by mechanically disrupting the organs
with a syringe plunger in cold PBS supplemented with 2 mM
EDTA and 0.1% FBS. Red blood cells were removed incubating
the cells in ACK lysis buffer for 5 min at 4uC. Splenocytes and
thymocytes were washed in cell culture medium (RPMI 1640
supplemented with 10% FBS, 10 mM HEPES, 2 mM L-
Glutamine, 1 mM sodium pyruvate, 1% non essential aminoacids,
100 U/ml penicillin and 100 mg/ml streptomycin) and filtered
through a 70 mm nylon cell strainer. Cells were adjusted to a final
concentration of 106 cells/ml. Spleen cells were stimulated for 3, 6
and 24 hours with anti-IgM F(ab9)2 fragment (1 mg/ml; Jackson
immunoresearch).
Preparation of mononuclear cells from human peripheral
blood
4 mL of human peripheral blood collected in K3EDTA
Vacutainers (BD) were used to isolate mononuclear cells by Ficoll
density gradient centrifugation using Ficoll-PaqueTM (Miltenyi
Biotec) and following the manufacturer’s instructions. Isolated cells
were analyzed using Cytospin and Fast Panoptic Staining
(Panreac). Only those preparations containing $90% of mono-
nuclear cells were used for the analysis.
Molecular Biology Analysis
Total RNA was isolated using TrizolTM (Invitrogen) and
following the manufacturer’s instructions. The quality of the
RNA was evaluated in a Bioanalyzer and quantitated in a
Nanodrop. The RNA used had a ratio of the absorbance at 260
and 280$1.8 and a RNA integrity number (RIN) $8. Relative
mRNA expression levels of PGC-1a, cytochrome c (Cyt c) and Mn
superoxide dismutase (MnSOD) were determined by quantitative
PCR of retro transcribed cDNA (qRT-PCR) with specific primers
as previously described [24]. Whole cell extracts were used to
analyze protein levels. PGC-1a, Cyt c and MnSOD protein levels
in mouse splenocytes were determined by western blot using
specific antibodies. The Zeptosens reverse array platform was used
to quantify Cyt c protein levels is human samples.
Mitochondria
Mitochondrial mass was estimated using MitoTracker Green
labeling. In short, 2.56105 splenocytes were incubated in 96-well
U- bottom plates with 0.1 mM MitoTracker Green (Invitrogen) in
PBS for 30 min at 37uC, washed twice with PBS and fixed with
4% paraformaldehyde for 15 min at 4uC. A FACSCantoTM II
cytometer (Becton Dickinson) was used to measure fluorescence
intensity of $20.000 events per sample. Data was analyzed using
the FACSDiva software (Becton Dickinson).
Ethics
The human experimental protocols were approved by the
Institutional Ethical Committee of the Instituto de Salud Carlos III
(ISCIII) and the CHGUV (Permit number PI 10/09). All patients
signed a written informed consent form. The animal experimental
protocols were approved by the Institutional Animal Care and Use
Committee of the CNIC (Permit number PA 13/09), and all
efforts were made to minimize suffering. All procedures conformed
to the Declaration of Helsinki and the NIH guidelines for animal
care and use (NIH publication No. 85-23).
Statistics
Statistical analyses were performed using SPSS for Windows,
release 17.0 (SPSS Inc., Chicago, IL). Levene’s test for equality of
variances and t-test for equality of means were used. All p-values
refer to two-tailed tests of significance; p, 0.05 was considered
significant.
Results
To determine if PGC-1a levels are induced during lymphocyte
activation we used a mouse model. First, we evaluated if PGC-1a
mRNA could be detected in total splenocyte, thymocytes and
lymph nodes from mice. We found that although PGC-1a mRNA
was detectable in both preparations PGC-1a levels were about 15
fold higher in splenocytes than in thymocytes and lymph nodes
(Fig. 1A). Next, we tested whether PGC-1a protein could be
detected in mouse splenocytes. A protein band of the predicted
molecular weight could be detected by western blot with a specific
antibody (Fig. 1B). In order to asses if this band was in fact PGC-
1a, a preparation of total splenocytes from PGC-1a2/2 mice was
used as negative control. We confirmed that the band was missing
from PGC-1a2/2 splenocytes and therefore we concluded that
PGC-1a is present in mouse splenocytes (Fig. 1B).
To evaluate if the detected PGC-1a protein was playing an
active role in the metabolic control of the splenocytes, we tested by
western blot the expression levels of well characterized molecular
targets of PGC-1a. Cyt c, that is part of the mitochondrial electron
transport chain [10], and the detoxification enzyme MnSOD [24]
and both were also found to be reduced in the total nuclear
fraction of blood samples from PGC-1a2/2 mice, suggesting that
PGC-1a is not only present, but is active in splenocytes (Fig. 1B).
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We further analyzed the mitochondrial content of murine
splenocytes from PGC-1a+/+ and PGC-1a2/2 mice. The cells
were labeled with MitoTracker Green, a non-membrane poten-
tial-dependent fluorescent marker, and analyzed by flow cytom-
etry. The results show that PGC-1a2/2 splenocytes have as an
average 20% less mitochondrial content than the PGC-1a+/+
splenocytes, indicating that the absence of PGC-1a has a net
impact on the number of mitochondria in splenocytes (Fig. 1C).
Finally, we tested if PGC-1a levels were modified upon
lymphocyte activation. First we examined the change in total
PGC-1a levels upon stimulation of total splenocytes with specific
stimuli for B lymphocytes (a-IgM). Splenocytes stimulated with a-
IgM showed an increase in both PGC-1a and Cyt c mRNA levels
3 h post stimulation, (Fig. 1D). We concluded that PGC-1a
expression is induced upon B cell stimulation. These results support
the notion that PGC-1a is present and active in lymphocytes and its
levels and activity are induced following lymphocyte stimulation.
In order to evaluate if we could detect the induction of PGC-1a
expression following STEMI, we isolated total mRNA from blood
mononuclear cells, isolated immediately upon admission and 72 h
later. PGC-1a levels were monitored by qRT-PCR. We found that
the samples segregated in two groups, those that induced PGC-1a
and those that did not (#1/.1). The induction group was further
subdivided in those that induced PGC-1a up to 10 fold (1–10), and
those that induced it more ($10) (Fig. 2A). To monitor PGC-1a
activity we also determined the induction of the PGC-1a target
genes Cyt c and MnSOD. We found that following STEMI not
only PGC-1a but also Cyt c and MnSOD mRNA levels were
increased (Fig. 2B–C), suggesting that not only PGC-1a mRNA
levels are higher, but also its transcriptional activity is elevated
following STEMI. This notion is further supported by the
observation that the induction of both Cyt c and MnSOD is
significantly higher in those patients that induced PGC-1a
expression more than 10 fold. To confirm the significance of this
observation Cyt c protein levels were directly monitored in whole
cell extracts from blood mononuclear cells, and were found to be
significantly elevated following STEMI only in the group of
patients that induced PGC-1a expression more than 10 fold
(Fig. 2D).
Importantly, we noted that the induction of PGC-1a after
STEMI inversely correlated with the mRNA levels of both PGC-
1a and Cyt c at the time of admission (Fig. 3), suggesting that
reduced basal PGC-1a activity, would result in stronger inductions
following STEMI.
Figure 1. PGC-1a mRNA is induced in mouse splenocytes following stimulation with aIgM. A) PGC-1a is present in mouse splenocytes and
tymocytes. Relative PGC-1a mRNA levels mouse splenocytes and tymocytes. B) Whole cell extracts of total splenocytes isolated from PGC-1a+/+ and
PGC-1a2/2 mice analyzed by western blot with specific antibodies against PGC-1a, Cyt c, MnSOD and b-actin as loading control. C) Total splenocytes
isolated from PGC-1a+/+ and PGC-1a2/2 mice were labeled with MitoTracker Green and analyzed by flow cytometry. D) Total splenocytes isolated
from C57BL6 mice were stimulated with aIgM for 3 h. Total RNA was extracted and PGC-1a and Cyt c mRNA levels were analyzed by qRT-PCR. Data
are means +/2SD. (*) p,0.05.
doi:10.1371/journal.pone.0026913.g001
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Figure 2. PGC-1a induction after STEMI correlates with Cyt c and MnSOD induction. A) PGC-1a mRNA levels, B) MnSOD mRNA levels, C)
Cyt c mRNA levels, D) Cyt c protein levels, in the blood mononuclear fraction of 37 STEMI patients right after hospital admission (t = 0) and 72 h later
(t = 72 h). Samples were grouped according to the induction rate of PGC-1a mRNA leves after STEMI (PGC-1a mRNA 72 h/PGC-1a mRNA 0 h) in three
groups, those that did not induce PGC-1a (#1), those that induced PGC-1a up to 10-fold (1–10) and those that induced PGC-1a more that 10-fold
($10). Data are means +/2SD. n.s = non statistically significant. Significance: p,0.05.
doi:10.1371/journal.pone.0026913.g002
Figure 3. PGC-1a induction after STEMI negative correlates with PGC-1a basal levels. The graph shows average Cyt C and PGC-1a mRNA
levels at the time of hospital admission in the three groups of PGC-1a induction.
doi:10.1371/journal.pone.0026913.g003
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To evaluate the functional significance of PGC-1a induction,
expression of PGC-1a was compared with: blood levels of
biomarkers (maximum values of TnI and CK-MB), echocardio-
graphic parameters (LVEF and RWMA), and infarct size estimated
by LGE in the CMR study. We found that induction of PGC-1a
expression 72 h after STEMI correlates with bigger infarcted areas
(% of necrotic area: 24.91 vs 10.9%) (Fig. 4A) and with higher
enzymatic peak (TnI 119.87 vs 63.01 ng/ml and CKMB 474.08 vs
170.73 ng/mL) (Fig. 4B), suggesting that induction of PGC-1a
expression is part of the cellular response to a STEMI.
PGC-1a induction tends to be more frequent in patients with
altered glucose metabolism and correlates with higher C-reactive
protein (CRP) levels, although the differences do not reach
statistical significance (Fig. 4D and Fig. 5).
Importantly, we also found that induction of PGC-1a
expression 72 h after STEMI correlates with more ventric-
ular dysfunction, with reduced LVEF, 53.96 vs 47.41% (Fig. 6A),
and increased RWMA (1.43 vs 1.79). Remarkably, left ventric-
ular dysfunction is more frequent in patients with a strong PGC-
1a induction, independently of the localization of the necrotic
area and despite the bigger size of the anterior infarctions
(Fig. 6C). This important observation may relate both to a
stronger immune response, and to a lower systemic level of
PGC-1a.
Figure 4. Patients that induce PGC-1a after STEMI have bigger necrotic areas. A) Necrotic areas as estimated by late gadolinium
enhancement (LGE). The infarct sizes, of the cohort of STEMI patients under survey, was determined by LGE on cardiac RMN (CMR). The estimated
mean infarct size for patients that induced PGC-1a levels (PGC-1a 72 h/0 h $1) is compared to that of patients that did not induce PGC-1a (PGC-1a
72 h/0 h #1) after STEMI. B–D) PGC-1a induction positively correlates with cardiac necrosis as estimated by TnImax (B), CKMBmax (C), and CRP plasma
levels (D). TnImax, CKMBmax, and CRP levels of the cohort of STEMI patients under survey The estimated mean for patients that induced PGC-1a levels
(PGC-1a 72 h/0 h $1) is compared to that of patients that did not induce PGC-1a (PGC-1a 72 h/0 h #1) after STEMI. Data are means +/2SD. (*)
p,0.05.
doi:10.1371/journal.pone.0026913.g004
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In order to evaluate if the observed induction of PGC-1a
monitored gross differences in the immune response after STEMI,
the total and relative blood count of total leukocytes, lymphocytes
and monocytes were monitored at t = 0 h and t = 72 h. As
previously noted a relative lymphocyte count tends to be reduced
after 72 h while the monocyte count tends to be increased. No
major differences were observed between the group of patients
that induced PGC-1a and the group that did not, indicating that
the observed increase in PGC-1a is likely a specific induction of its
expression and not just a reflection of changes in the number of
leukocytes following STEMI (Fig. 7).
Discussion
This study suggests that the monitorization of PGC-1a mRNA
levels has potential interest as a novel marker for the recovery after
STEMI, since high t = 0 PGC-1a levels and absence of PGC-1a
induction 3 days following STEMI, strongly correlate with
reduced cardiac injury. Furthermore, our data show that PGC-
1a mRNA levels can be readily detected in blood mononuclear
cell samples and are a good indicator of its activity.
Recovery of the cardiomyocyte oxidative capacity is crucial
during the reperfusion phase after STEMI. PGC-1a is a master
regulator of cellular oxidative metabolism. Since PGC-1a has been
found in lymphocytes, and induction of the immune system is also
a key factor in the STEMI recovery phase, we decided to evaluate
if PGC-1a induction could be detected in human patients after
STEMI. We found a good correlation between its post-hypoxic
expression and the size of the infarcted area.
38 patients were prospectively selected with STEMI diagnostic
that underwent a re-perfusion procedure. Blood samples were
obtained right after their arrival to the hospital and 72 h later,
being processed for RNA isolation. PGC-1a mRNA levels were
analyzed by qRT-PCR. Expression of PGC-1a in blood
mononuclear cells was compared with the severity of the cardiac
injury estimated by: enzymatic peak, LVEF and necrotic area
determined by LGE-CMR. We found that induction of PGC-1a
in blood mononuclear cells positively correlates with higher levels
of myocardium damage, a more severe left ventricular dysfunc-
tion, a higher RWMA score, and larger necrotic areas. This
observation showed that PGC-1a induction can be detected in
human blood mononuclear cells as part of the response to an
STEMI, and suggested that PGC-1a is induced in the immune
system (Table 1 and 2).
Interestingly, PGC-1a induction tends to be more frequent in
patients with altered glucose metabolism and higher C-reactive
protein (CRP) levels. CRP is generally acknowledged as an
important predictor of vascular death and has been shown to allow
reliable risk stratification of STEMI patients [25]. Elevated PGC-
1a mRNA levels have been previously reported in the liver of
diabetic patients [26]. However, metabolic data in diabetic
patients is generally consistent with a loss of PGC-1a activity
[27]. This apparent paradox may be related to the well-established
observation that diabetic patients have a chronic basal activation
of the immune system [28].
Although there were no major differences in the immune
response between the groups, some significant differences where
observed. The induction group had significantly more lympho-
Figure 5. PGC-1a induction correlates with higher plasma glucose levels in the cohort of STEMI patients under survey. The estimated
mean for patients that induced PGC-1a levels (PGC-1a 72 h/0 h$1) is compared to that of patients that did not induce PGC-1a (PGC-1a 72 h/0 h#1)
after STEMI. Data are means +/2SD. (*) p,0.05.
doi:10.1371/journal.pone.0026913.g005
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cytes at the time of hospitalization, and the increase in monocyte
count at t = 72 h was significantly more pronounced in the
induction group Although the significance of these differences
requires further evaluation, it is likely that they may just be the
correlate of a more severe cardiac damage.
Neutrophils, lymphocytes andmonocytes are part of this response
with neutrophil’s count peak 12 h post-infarction, lymphocytes and
monocytes 48 h post-infarction. PGC-1a has been previously found
in human lymphocytes. To directly test if PGC-1a is induced in
stimulated leukocytes we measured PGC-1a levels in murine
splenocytes and we found that PGC-1a levels were induced
following B-cell receptor (BCR) stimulation. These results support
the notion that induction of PGC-1a in lymphocytes could be part
of the immune activation that follows an STEMI. A possible role of
PGC-1a in lymphocyte activation is supported by different
observations. For example, oxygen consumption is increased in B
lymphocytes following IgM activation [29], and mitochondrial
activity is associated with T cell activation [30,31,32].
It should be noted that no changes in PGC-1a levels can
be detected in murine splenocytes at times shorter than 3 h
post-stimulation. Since patients with a latency time of over
150 min were excluded from the study, we believe that the values
detected in human blood mononuclear cells at the time of the
patient admission are a close correlate of the normal the basal
levels for the patient. Nevertheless, this remains an estimate that
cannot unfortunately be fixed, since it was not possible to get blood
samples of the patients before the STEMI.
Overall, we interpret these results as an indication that PGC-1a
expression is induced as part of the immune responsiveness
following myocardial infarction in humans, and furthermore, they
possibly suggest that low basal PGC-1a levels negatively correlate
with cardiac damage. Following myocardial infarction an
inflammatory cascade is activated and circulating total white
blood cell counts increase dramatically. Larger infarct sizes and
adverse outcomes correlate with white blood cell count in STEMI.
Results obtained with animal models and in vitro cell assays have
shown that reduced blood flow and reduced oxygen tension induce
PGC-1a, and conversely PGC-1a is necessary to induce
angiogenesis and recover the tissue capacity to access and use
oxygen, as well as to maintain muscle contraction capacity, while
Figure 6. PGC-1a induction positively correlates with cardiac ventricular dysfunction. A) LVEF and B) RWMA, were determined by
ecocardiography. The estimated mean for patients that induced PGC-1a levels (PGC-1a 72 h/0 h $1) is compared to that of patients that did not
induce PGC-1a (PGC-1a 72 h/0 h #1) after STEMI. C) Antero-lateral infarcts are associated to larger necrotic areas than inferior-posterior infarcts as
determine by LGE on CRM. The graph shows mean LVEF and necrotic area (LGE) of patients with antero-lateral or inferior-posterior infarcts. Data are
means +/2SD. (*) p,0.05.
doi:10.1371/journal.pone.0026913.g006
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Figure 7. STEMI patients that induce PGC-1a do not show gross differences in the number of leukocytes. Total number of leukocytes,
lymphocytes, and monocytes in blood samples of patients at the time of hospitalization (t = 0) and 72 h later. The estimated mean for patients that
induced PGC-1a levels (PGC-1a 72 h/0 h $1) is compared to that of patients that did not induce PGC-1a (PGC-1a 72 h/0 h #1) after STEMI. Data are
means +/2SD. (*) p,0.05.
doi:10.1371/journal.pone.0026913.g007
Table 1. Demographic data, Biochemistry and CMR Characteristics of the Patients with and without PGC-1a Induction.
PGC-1a mRNA 72 h/0 h .1 (n = 12) PGC-1a mRNA 72 h/0 h #1 (n = 26) p value
Base line characteristics
Age (years) 61.08 (sd 3.03) 60.88 (sd 2.33) 0.959
Males sex (%) 10 (83.3%) 22 (84.6%) 0.924
Diabetes (%) 5 (41.7%) 8 (30.8%) 0.541
Hypertension (%) 9 (75%) 18 (69.2%) 0.722
Hypercholesterolemia (%) 6 (50%) 14 (53.8%) 0.834
Current smoker (%) 6 (50%) 15 (57.7%) 0.674
Coronary event
Mean time to reperfusion (minutes) 189 (137–242) 184 (160–208) 0.942
Median troponin I peak value (ng/mL) 119.87 (97–143) 63.01 (52–74) 0.039
Median creatine kinase MB peak value (ng/mL) 474.08 (264–684) 170.73 (148–193) 0.043
Elective ACTP (%) 3 (25%) 10 (38%) 0.417
Rescue ACTP (%) 7 (58.4%) 4 (16%) 0.006
Reperfusion by thrombolysis (%) 2 (16.6%) 12 (46%) 0.084
Anterior infarction (%) 8 (66.6%) 9 (34.6%) 0.075
Biochemistry (plasma)
Creatinine (mg/dL) 1.03 (0.95–1.11) 1.01 (0.97–1.05) 0.811
Haemoglobine (mg/dL) 13.10 (12.6–13.6) 13.86 (13.4–14.3) 0.249
Cholesterol (mg/dL) 177.08 (165–189) 180.92 (170–191) 0.812
LDLc (mg/dL) 116.50 (107–126) 122.19 (115–130) 0.642
HDLc (mg/dL) 38.58 (37–40) 36.23 (35–38) 0.269
Glucose (mg/dL) 120.83 (113–128) 105.26 (102–109) 0.091
CRP (mg/dL) 0.98 (0.71.1.25) 0.64 (0.57–0.71) 0.126
Ecocardiography and magnetic resonance
Ejection fraction by echocardiography (%) 47.41 (sd 2.2) 53.96 (sd 1.6) 0.025
Score regional wall motion abnormalities 1.79 (sd 0.1) 1.43 (sd 0.1) 0.013
Left ventricle ejection fraction ,35% (%) 16.6 (sd 11.2) 3.8 (sd 0.4) 0.136
Late gadolinium enhancement by CMR (%) 24.91 (sd 6.3) 10.90 (sd 2.1) 0.012
Data are means +/2SD. n.s = non statistically significant. Significance: p,0.05.
doi:10.1371/journal.pone.0026913.t001
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its absence leads to heart failure. These results, although highly
informative lack so far a human correlate, mainly due to the
obvious need and impossibility to take human heart samples. Our
results now open a new window of possibilities since the
observation that PGC-1a induction can be observed in the
mononuclear cells of blood samples makes now feasible to test if
PGC-1a has in fact a prognostic value for cardiac recovery.
It is widely accepted that metabolic dysfunctions, where PGC-
1a levels are reduced, are an important risk factor for
cardiovascular disease. Our results suggest that PGC-1a activity
is also likely to be relevant in the limitation of cardiac damage
following an STEMI, and that its monitorization is feasible and
likely to be a relevant prognosis factor both for cardiovascular
disease and for the extent of cardiac damage following STEMI.
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